Oral Hormone Therapy for Advanced Prostate Cancer
The FDA approved the first once-a-day pill to lower the levels of testosterone in certain patients with prostate cancer....
Progress Against Cancer
The FDA approved the first once-a-day pill to lower the levels of testosterone in certain patients with prostate cancer....
The FDA approved the molecularly targeted therapeutic selinexor to be used in combination with another targeted agent and a...
The FDA has approved a new targeted therapeutic for certain patients with HER2-positive breast cancer who were previously treated with other targeted therapies....
The FDA has expanded the approval of a molecularly targeted therapeutic to treat certain pediatric and adult patients with...
Roughly 6 percent of men and women in the United States will be diagnosed with lung and bronchus cancer...
The FDA approved the use of an immunotherapeutic in combination with chemotherapy to treat certain patients with triple-negative breast...
The FDA granted approval to expand the use of a minimally invasive biomarker test to identify certain patients with ovarian,...
The FDA approved a combination of two immune checkpoint inhibitors to treat adult patients with unresectable malignant pleural mesothelioma....
The FDA approved the first liquid biopsy companion diagnostic that uses next-generation sequencing to test for EGFR gene mutations...
The FDA has approved the first targeted therapeutic against B-cell maturation antigen (BCMA) to treat certain patients with multiple...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn MoreYour donation to the American Association for Cancer Research helps our more than 47,000 members worldwide drive progress against cancer.
Donate Now